Aprea Therapeutics was built on the belief that targeted therapies can fundamentally transform the treatment of cancer and improve outcomes for patients. This ambitious philosophy, rooted in our inception, remains at the core of our corporate DNA today.
Business Development at Aprea Therapeutics
Our conviction in DNA Damage Response (DDR) and p53 as therapeutic targets, and our commitment to the development and commercialization of novel targeted anti-cancer therapies, guides our approach to partnerships and external collaborations with companies and academic institutions worldwide.
We welcome the opportunity to discuss how we can work together to continue revolutionizing cancer treatment. To explore partnering opportunities with Aprea, please contact us at partnering@aprea.com.